The patent, when formally approved, will reinforce protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added ...

Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration ...

Incident use of gabapentin is not associated with an increase in fall-related hospital visits compared with duloxetine ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

For people suffering from chronic knee pain, especially those over 50, a new treatment is offering hope and relief.

IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing ...

A New Discovery About Pain Signaling May Contribute to Better Treatment of Chronic Pain Nov. 18, 2024 — When pain signals are passed along the nervous system, proteins called calcium channels ...

A raw and honest look at one woman's decades-long struggle with pain and undiagnosed fibromyalgia, and the breakthrough ...

Though researchers still don’t know what causes the disorder, studies show that people with fibromyalgia have an increased ...

Core offers FDA-approved nVNS devices with growth potential in healthcare and military markets. Click here to find out what ...

The FDA has accepted the NDA for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.